1、评价健康受试者单次静脉滴注注射用HCP002的耐受性及安全性；2、比较等摩尔剂量的注射用HCP002与注射用伏立康唑在健康人体的耐受性及安全性；3、评价单次静脉滴注给药后HCP002的药代动力学特征；4、评价注射用HCP002单次静脉滴注给药后转化为伏立康唑的药代动力学特征；5、比较等摩尔剂量的注射用HCP002与注射用伏立康唑的药代动力学特征

开始日期-

申办/合作机构

华创合成制药股份有限公司

100 项与 HCP-002 相关的临床结果

登录后查看更多信息

100 项与 HCP-002 相关的转化医学

登录后查看更多信息

100 项与 HCP-002 相关的专利（医药）

登录后查看更多信息

项与 HCP-002 相关的文献（医药）

2022-03-01·Bioanalysis4区 · 医学

LC-MS/MS Methods to quantify HCP002 in Human Plasma and Urine: Applications in a Pharmacokinetic Study

4区 · 医学

Article

作者: Zhang, Ye ; Wang, Yong-Qing ; Sun, Lu-Ning ; Fang, Qiu-Chen ; Chen, Chao ; Li, Xue ; Zhang, Hong-Wen ; Shen, Ye

Aim: HCP002, a phosphate-modified derivative of voriconazole, can improve solubility without using the nephrotoxic solubilizer, sulfobutylether-β-cyclodextrin. To study pharmacokinetics in humans, LC-MS/MS methods to quantify HCP002 in human plasma and urine were developed and validated. Method: After protein precipitation by acetonitrile containing voriconazole-d₃, HCP002 was separated on a ZORBAX SB-Aq column, and LCMS/MS analysis was performed in multi-response monitoring mode. Results: The analytical run time was 3 min. Linearity was observed over the ranges of 0.100-40.0 and 0.400-200 μg/ml in plasma and urine, respectively. Precision and accuracy were within acceptable limits. Sample stability was confirmed. Conclusion: Rapid and reproducible methods quantified HCP002 in urine, and plasma samples were established.

2014-03-01·Carbohydrate Polymers1区 · 化学

Structural characterization and immunomodulatory effect of a polysaccharide HCP-2 from Houttuynia cordata

1区 · 化学

Article

作者: Wang, Yi-Fen ; Zhou, Xuelin ; Fung, Kwok-Pui ; Leung, Ping-Chung ; Chan, Judy Yuet-Wa ; Wan, David Chi-Cheong ; Lau, Clara Bik-San ; Lin, Huang-Quan ; Chan, Ben Chung-Lap ; Cheng, Bao-Hui ; Han, Xiao-Qiang

Immunomodulation of natural polysaccharides has been the hot topic of research in recent years. In order to explore the immunomodulatory effect of Houttuynia cordata Thunb., the water extract was studied and a polysaccharide HCP-2 with molecular weight of 60,000 Da was isolated by chromatography using DEAE Sepharose CL-6B and Sephacryl S-500 [corrected] HR columns. The structure characterization of HCP-2 was performed by Fourier transform infrared spectroscopy (FTIR), acidic hydrolysis, PMP derivation, HPLC analysis and nuclear magnetic resonance spectra (NMR). HCP-2 was elucidated as a pectic polysaccharide with a linear chain of 1,4-linked α-D-galacturonic acid residues in which part of the 6-carboxyl groups were methyl esterified and part of 2-hydroxyl groups were acetylated. The bioactivity assays showed that HCP-2 could increase the secretions of interleukin-1β (IL-1β), tumor necrosis factor-α (TNF-α), macrophage inhibitory protein-1α (MIP-1α), macrophage inhibitory protein-1β (MIP-1β), and RANTES (regulated on activation, normal T cell expressed and secreted) in human peripheral blood mononuclear cells (PBMCs), which play critical roles in the innate immune system and shape the adaptive immunity. Our results implied that HCP-2 could be an immune enhancer.

100 项与 HCP-002 相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
念珠菌血症	临床1期	中国	华创合成制药股份有限公司	2018-01-02
侵袭性曲霉菌病	临床1期	中国	华创合成制药股份有限公司	2018-01-02